Blood test could decide who needs more chemo after oral cancer treatment
NCT ID NCT07296250
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This trial is for people with oral cancer who have completed surgery and standard chemoradiation. Researchers will use a blood test to look for leftover cancer cells (circulating tumor cells). If the test is positive, patients will receive three months of low-dose oral chemotherapy, with the option to continue up to a year if the cells persist. The goal is to see if this personalized approach can improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linkou Chang Gung Memorial Hospital
RECRUITINGTaoyuan City, 333423, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose oral chemotherapy
What this could lead to
If successful, this could provide a way to personalize post-treatment care for oral cancer patients, potentially improving survival by catching and treating remaining cancer cells early.
What could go wrong
This is a small, early-phase trial with only 100 participants, so results may not apply to all patients. The approach relies on a new test (circulating tumor cells) that is still being validated, and the benefit of extended chemotherapy is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.